CN101941964A - 具有促进功效的趋化因子受体结合的杂环化合物 - Google Patents

具有促进功效的趋化因子受体结合的杂环化合物 Download PDF

Info

Publication number
CN101941964A
CN101941964A CN2010102549975A CN201010254997A CN101941964A CN 101941964 A CN101941964 A CN 101941964A CN 2010102549975 A CN2010102549975 A CN 2010102549975A CN 201010254997 A CN201010254997 A CN 201010254997A CN 101941964 A CN101941964 A CN 101941964A
Authority
CN
China
Prior art keywords
terpyridyl
dimethyl
tetrahydrochysene
compound
meso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010102549975A
Other languages
English (en)
Chinese (zh)
Inventor
G·J·布里杰
E·J·麦基切恩
R·斯基勒
D·斯古尔斯
I·贝尔德
A·凯勒
C·哈维格
Y·朱
G·陈
K·斯库平斯卡
M·梅茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anormed Inc
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of CN101941964A publication Critical patent/CN101941964A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010102549975A 2003-04-22 2004-04-22 具有促进功效的趋化因子受体结合的杂环化合物 Pending CN101941964A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46485803P 2003-04-22 2003-04-22
US60/464,858 2003-04-22
US50523003P 2003-09-22 2003-09-22
US60/505,230 2003-09-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200480010845 Division CN1777423A (zh) 2003-04-22 2004-04-22 具有促进功效的趋化因子受体结合的杂环化合物

Publications (1)

Publication Number Publication Date
CN101941964A true CN101941964A (zh) 2011-01-12

Family

ID=33313500

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010102549975A Pending CN101941964A (zh) 2003-04-22 2004-04-22 具有促进功效的趋化因子受体结合的杂环化合物

Country Status (16)

Country Link
US (2) US7550484B2 (enExample)
EP (2) EP1615633B1 (enExample)
JP (1) JP4778420B2 (enExample)
KR (1) KR20050115455A (enExample)
CN (1) CN101941964A (enExample)
AU (1) AU2004232361A1 (enExample)
BR (1) BRPI0409655B8 (enExample)
CA (1) CA2517077C (enExample)
ES (1) ES2393188T3 (enExample)
IL (1) IL170207A (enExample)
IN (1) IN266744B (enExample)
MX (1) MXPA05011353A (enExample)
NO (1) NO20054405L (enExample)
NZ (1) NZ542850A (enExample)
RU (1) RU2005136224A (enExample)
WO (1) WO2004093817A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275071A (zh) * 2013-05-17 2013-09-04 山西大学 一种香豆素衍生物及其制备方法和用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615633B1 (en) * 2003-04-22 2012-08-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
BRPI0514343A (pt) * 2004-08-13 2008-06-10 Anormed Inc combinações de quimiocinas para mobilizar células progenitoras/tronco
EP1838321A4 (en) 2005-01-07 2009-03-18 Univ Emory CXCR4 ANTAGONISTS FOR THE TREATMENT OF HIV INFECTION
WO2007025166A2 (en) * 2005-08-25 2007-03-01 Repair Technologies, Inc. Devices, compositions and methods for the protection and repair of cells and tissues
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
PL1961744T3 (pl) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Związek zawierający grupę zasadową oraz jego zastosowanie
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
MX2009001272A (es) * 2006-08-02 2009-02-11 Genzyme Corp Terapia de combinacion.
BRPI0715393A2 (pt) * 2006-08-07 2013-06-25 Genzyme Corp terapia de combinaÇço
CN102015717A (zh) 2008-03-28 2011-04-13 奥蒂瑞斯治疗公司 趋化因子受体调节剂
US20170105969A1 (en) * 2014-06-02 2017-04-20 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) * 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109562106B (zh) * 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CN114206869A (zh) * 2019-06-26 2022-03-18 X4 制药有限公司 Cxcr4抑制剂和其用途
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATING NEUTROPENIA
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
US5235056A (en) 1992-04-22 1993-08-10 Ciba-Geigy Corporation Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
DE60028354T2 (de) 1999-03-24 2007-02-08 Anormed Inc., Langley Chemokine rezeptor bindende heterozyklische verbindungen
PT1307455E (pt) * 1999-10-20 2005-06-30 Tanabe Seiyaku Co Inibidores de adesao celular mediada por (alfa)l (beta)2
AU5811001A (en) * 2000-05-09 2001-11-20 Univ British Columbia Cxcr4 antagonist treatment of hematopoietic cells
WO2002022599A2 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
BR0113930A (pt) 2000-09-15 2003-06-24 Anormed Inc Compostos heterocìclicos de ligação aos receptores de quimiocina
EP1317451B1 (en) 2000-09-15 2006-08-09 Anormed Inc. Chemokine receptor binding heterocyclic compounds
GB0030673D0 (en) * 2000-12-15 2001-01-31 Unilever Plc Ligand and complex for catalytically bleaching a substrate
JP2002284779A (ja) * 2001-01-18 2002-10-03 Sankyo Co Ltd ヘテロアリール置換ピロール誘導体を含有する医薬
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
US7491544B2 (en) * 2002-05-20 2009-02-17 New York University Chiral piperidine and quinucledine ligands
EP1615633B1 (en) * 2003-04-22 2012-08-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
US10468384B2 (en) 2017-09-15 2019-11-05 STATS ChipPAC Pte. Ltd. Semiconductor device and method of forming embedded die substrate, and system-in-package modules with the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103275071A (zh) * 2013-05-17 2013-09-04 山西大学 一种香豆素衍生物及其制备方法和用途
CN103275071B (zh) * 2013-05-17 2015-04-15 山西大学 一种香豆素衍生物及其制备方法和用途

Also Published As

Publication number Publication date
US20050059702A1 (en) 2005-03-17
EP2374804A1 (en) 2011-10-12
BRPI0409655B8 (pt) 2021-05-25
JP4778420B2 (ja) 2011-09-21
KR20050115455A (ko) 2005-12-07
BRPI0409655B1 (pt) 2019-12-03
NO20054405D0 (no) 2005-09-22
MXPA05011353A (es) 2005-11-28
HK1089930A1 (en) 2006-12-15
NZ542850A (en) 2007-12-21
AU2004232361A1 (en) 2004-11-04
ES2393188T3 (es) 2012-12-19
EP1615633A4 (en) 2008-07-09
US20090281308A1 (en) 2009-11-12
RU2005136224A (ru) 2006-06-10
WO2004093817A2 (en) 2004-11-04
JP2006524700A (ja) 2006-11-02
EP1615633A2 (en) 2006-01-18
IL170207A (en) 2011-06-30
WO2004093817A3 (en) 2005-04-28
NO20054405L (no) 2006-01-19
EP1615633B1 (en) 2012-08-15
BRPI0409655A (pt) 2006-04-18
CA2517077A1 (en) 2004-11-04
CA2517077C (en) 2013-03-12
IN266744B (enExample) 2015-05-29
US7550484B2 (en) 2009-06-23

Similar Documents

Publication Publication Date Title
CN101941964A (zh) 具有促进功效的趋化因子受体结合的杂环化合物
DE60218511T2 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
CA2389545C (en) Chemokine receptor binding heterocyclic compounds
CN1457339A (zh) 趋化因子受体结合性杂环化合物
CN101309690A (zh) 趋化因子受体结合化合物
CN102153540A (zh) 具有强效的与趋化因子受体结合的杂环化合物
US20160158188A1 (en) Novel use for pai-1 inhibitor
US7491735B2 (en) Chemokine receptor binding compounds
Miller et al. Discovery of tetrahydroisoquinoline-containing CXCR4 antagonists with improved in vitro ADMET properties
CN112409223A (zh) 酰胺类化合物及其作为sting抑制剂的医药用途
US7498346B2 (en) Chemokine receptor binding compounds
KR102386659B1 (ko) 심장 보호 효과를 갖는 신규 화합물 및 이를 이용한 줄기세포 배양용 배지조성물
US7790747B2 (en) Chemokine receptor binding compounds
JP2518965B2 (ja) 新規ピリジン誘導体及びそれを有効成分として含有する制癌剤効果増強剤
ZA200508518B (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
HK1089930B (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CN1980916A (zh) 结合趋化因子受体的杂环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110112